March 18, 2019
Alpine Immune Sciences Provides Corporate Update and Reports Full Year 2018 Financial Results
First Subjects Dosed in Phase I Clinical Trial for Lead Autoimmune/Inflammatory Disease Program, ALPN-101 Completed $25 Million Private Placement Strong…